Loading
A phase 3 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT06973187 by BeOne Medicines, with 500 participants planned, started 2025-09-04 and due to reach its primary completion in 2028-04-17. Interventions recorded: Tacabrutideg and Pirtobrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/